Indegene Limited
INDGN · 544172 · Healthcare · Healthcare Research, Analytics & Technology
- Market cap
- Rs 14,272 Cr
- P/E
- 34.66x
- P/B
- 4.25x
- 52W high / low
- Rs 627 / Rs 414
Our computed operating_margin (13.68%) diverges from BSE's own published figure (29.66%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.
About Indegene
Indegene Limited is listed on the NSE under the symbol INDGN and on the BSE under scrip code 544172. It is classified in the Healthcare sector, industry: Healthcare Research, Analytics & Technology. It is a constituent of BSE 500, NIFTY 500 and NIFTY Smallcap 250. The company listed on 13 May 2024 and has a face value of Rs 2.
The latest available end-of-day price is Rs 593.45 (−0.92% on the day), for a market capitalisation of Rs 14,272 Cr. Trailing P/E is 34.66x and price-to-book is 4.25x. The 52-week range is Rs 414 to Rs 627. The latest price is 84% of the way from the 52-week low to the 52-week high.
Against the 3-company comparison set from the official BSE basic industry Healthcare Research, Analytics & Technology, its market capitalisation is 1.0 times the peer median of Rs 14,272 Cr, and its P/E of 34.66x compares with a peer median of 34.66x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For Q2 FY27 (period ended 30 Sept 2026), Indegene Limited reported revenue of Rs 1,122 Cr, net profit of Rs 112 Cr and earnings per share of Rs 4.67.
On a trailing-twelve-month basis the filings add up to revenue of Rs 4,131 Cr, net income of Rs 411 Cr and a net margin of 9.95%.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Healthcare Research, Analytics & Technology. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Syngene International Limited | Rs 398.6 | Rs 16,091 Cr | Rs 3,613 Cr | Rs 186 Cr | 86.09x | 3.89% |
| Indegene LimitedThis company | Rs 593.45 | Rs 14,272 Cr | Rs 4,205 Cr | Rs 411 Cr | 34.66x | 14.29% |
| Suven Life Sciences Limited | Rs 264.2 | Rs 6,975 Cr | Rs 29.7 Cr | Rs -352.4 Cr | — | -100.50% |
| Median | Rs 593.45 | Rs 14,272 Cr | Rs 4,205 Cr | Rs 411 Cr | 34.66x | 14.29% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Indegene
Same official industry (Healthcare Research, Analytics & Technology)
Other Healthcare companies of a similar market capitalisation
- Pfizer LimitedPFIZER · Market cap Rs 17,201 Cr
- Eris Lifesciences LimitedERIS · Market cap Rs 16,139 Cr
- Vijaya Diagnostic Centre LimitedVIJAYA · Market cap Rs 15,066 Cr
- Jubilant Pharmova LimitedJUBLPHARMA · Market cap Rs 14,947 Cr
- Poly Medicure LimitedPOLYMED · Market cap Rs 14,818 Cr
- Natco Pharma LimitedNATCOPHARM · Market cap Rs 14,097 Cr
- Concord Biotech LimitedCONCORDBIO · Market cap Rs 12,874 Cr
- Rainbow Childrens Medicare LimitedRAINBOW · Market cap Rs 12,155 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.